A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN2246 in Healthy Volunteers
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Tolebrutinib (Primary)
- Indications Autoimmune disorders; CNS disorders; Inflammation; Multiple sclerosis
- Focus Adverse reactions; First in man
- 01 Mar 2019 According to a Principia Biopharma media release, results from this study were presented at the American Consortium for Therapy and Research in Multiple Sclerosis (ACTRIMS) annual meeting.
- 01 Mar 2019 Results presented in the Principia Biopharma media release.
- 16 Oct 2018 According to a Principia Biopharma media release, the company intends to present the results of this Phase I clinical trial at a future scientific conference.